Here, we investigated the broader role of this machinery in amyloid biology by testing its potential to process aggregates of amyloidogenic Tau isolated from AD brain, from a cell culture model, or produced in vitro and by characterizing more precisely the products of chaperone-mediated Tau disaggregation. The gene discussed is MAPT; the disease is Alzheimer disease.